These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33719882)

  • 21. Expanding global and national influenza vaccine systems to match the COVID-19 pandemic response.
    Ruscio BA; Hotez P
    Vaccine; 2020 Nov; 38(50):7880-7882. PubMed ID: 33121842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update From the Advisory Committee on Immunization Practices.
    O Leary ST; Maldonado YA; Kimberlin DW
    J Pediatric Infect Dis Soc; 2020 Dec; 9(6):645-649. PubMed ID: 33180938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A public health timeline to prepare for COVID-19 vaccines in Canada.
    MacDonald NE; Comeau J; Dubé E; Bucci L; Graham JE
    Can J Public Health; 2020 Dec; 111(6):945-952. PubMed ID: 33151510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Which Beliefs Predict Intention to Get Vaccinated against COVID-19? A Mixed-Methods Reasoned Action Approach Applied to Health Communication.
    Lueck JA; Spiers A
    J Health Commun; 2020 Oct; 25(10):790-798. PubMed ID: 33719876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on the global vaccine development for coronavirus.
    Rab S; Afjal ; Javaid M; Haleem A; Vaishya R
    Diabetes Metab Syndr; 2020; 14(6):2053-2055. PubMed ID: 33113472
    [No Abstract]   [Full Text] [Related]  

  • 27. COVID-19 vaccines: one step towards the beginning of the end of the global impact of the pandemic.
    Cook TM; Farrar JJ
    Anaesthesia; 2021 Apr; 76(4):435-443. PubMed ID: 33316853
    [No Abstract]   [Full Text] [Related]  

  • 28. Migraine treatment and COVID-19 vaccines: No cause for concern.
    Gelfand AA; Poland G
    Headache; 2021 Mar; 61(3):409-411. PubMed ID: 33543775
    [No Abstract]   [Full Text] [Related]  

  • 29. COVID-19: Coronavirus Vaccine Development Updates.
    Zhao J; Zhao S; Ou J; Zhang J; Lan W; Guan W; Wu X; Yan Y; Zhao W; Wu J; Chodosh J; Zhang Q
    Front Immunol; 2020; 11():602256. PubMed ID: 33424848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancing global health communication during a crisis: lessons from the COVID-19 pandemic.
    Ratzan SC; Sommariva S; Rauh L
    Public Health Res Pract; 2020 Jun; 30(2):. PubMed ID: 32601655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches.
    Tahir Ul Qamar M; Rehman A; Tusleem K; Ashfaq UA; Qasim M; Zhu X; Fatima I; Shahid F; Chen LL
    PLoS One; 2020; 15(12):e0244176. PubMed ID: 33351863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.
    Jin P; Li J; Pan H; Wu Y; Zhu F
    Signal Transduct Target Ther; 2021 Feb; 6(1):48. PubMed ID: 33531462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 basics and vaccine development with a Canadian perspective.
    Liu M; Chen X
    Can J Microbiol; 2021 Feb; 67(2):112-118. PubMed ID: 33136431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
    Sharma O; Sultan AA; Ding H; Triggle CR
    Front Immunol; 2020; 11():585354. PubMed ID: 33163000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. India begins COVID-19 vaccination amid trial allegations.
    Bhuyan A
    Lancet; 2021 Jan; 397(10271):264. PubMed ID: 33485435
    [No Abstract]   [Full Text] [Related]  

  • 37. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.
    Kang YF; Sun C; Zhuang Z; Yuan RY; Zheng Q; Li JP; Zhou PP; Chen XC; Liu Z; Zhang X; Yu XH; Kong XW; Zhu QY; Zhong Q; Xu M; Zhong NS; Zeng YX; Feng GK; Ke C; Zhao JC; Zeng MS
    ACS Nano; 2021 Feb; 15(2):2738-2752. PubMed ID: 33464829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Planning for a COVID-19 Vaccination Program.
    Schaffer DeRoo S; Pudalov NJ; Fu LY
    JAMA; 2020 Jun; 323(24):2458-2459. PubMed ID: 32421155
    [No Abstract]   [Full Text] [Related]  

  • 40. Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control.
    Salvamani S; Tan HZ; Thang WJ; Ter HC; Wan MS; Gunasekaran B; Rhodes A
    Br J Biomed Sci; 2020 Oct; 77(4):168-184. PubMed ID: 32942955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.